TD Cowen Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating

Moomoo NewsFeb 7 08:31 ET · Ratings

Sangamo Reports Updated Data for Gene Therapy Candidate ST-920

Seeking AlphaFeb 6 13:56 ET

Express News | Sangamo Therapeutics Inc - Isaralgagene Civaparvovec Generally Well-Tolerated With Most Adverse Events Grade 1-2

ReutersFeb 6 08:05 ET

Express News | Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile

ReutersFeb 6 08:05 ET

Expert Outlook: Sangamo Therapeutics Through The Eyes Of 11 Analysts

BenzingaJan 27 08:00 ET

H.C. Wainwright Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating, Maintains Target Price $10

Moomoo NewsJan 27 06:32 ET · Ratings